Preimplantation genetic testing (PGT) refers to a group of genetic tests that analyze the DNA of embryos for chromosomal or genetic anomalies prior to the transfer to the uterus during in vitro fertilization (IVF). Ontario Health conducted a series of health technology assessments (HTA) of PGT, including assessment of PGT-A, PGT-M, and PGT-SR. In this report, we summarize the findings common to all 3 HTAS, including a rapid review of the qualitative literature, direct patient engagement, and a review of published literature examining ethical considerations relating to PGT. We also undertook a rapid review of the obstetrical and neonatal harms of PGT using trophectoderm biopsy. Reviews of the clinical and economic impact of PGT-A, the clinical impact of PGT-M, and the clinical impact of PGT-SR have been published separately.